Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN 2019 Symposium /
Oncobox, RNA sequencing and molecular pathway analysis-base system for prescription of target drugs to advanced cancer patients

23rd - 24th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.07.19
Views: 344

Dr Anton Buzdin - Sechenov Moscow First Medical University, Moscow, Russia

Dr Anton Buzdin speaks to ecancer at the WIN 2019 Symposium in Paris about the preliminary results generated from a trial using RNA sequencing data, and molecular pathway analysis to recommend targeted drugs for patients based on an oncobox-generated rating.

Following this, Dr Buzdin explains that clinicians had the choice to follow these recommendations or not, before being followed up to assess the clinical responses of these patients.

He also describes the results of this study, in which it was found that RNA-guided therapies were significantly more efficient, compared to standard of care ones.

Dr Buzdin mentions that future trials should focus on the use of transcriptomic and genomic profiling to obtain improved clinical responses when compared to conventional therapies.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation